Blood plasma is the liquid component of blood constituting of water along with plasma components such as immunoglobulin, electrolytes, glucose, clotting factors, electrolytes, and hormones. It plays a crucial role in maintaining the electrolyte and osmotic balance while preventing infection and blood disorders in the body. Plasma derivatives are the concentrates of specific proteins, which require pooling of plasma from large number of donors. For instance, they require more than hundred plasma donations to produce sufficient immunoglobulin to treat an immune-deficient patient for one year. They are obtained by the process of fractionation where protein concentrates are separated and then clinically used.
The growth of the global blood plasma derivatives market is majorly driven by increase in prevalence of life-threatening disorders, especially hemophilia. Other factors boosting the market growth include rise in adoption of blood plasma derivatives products, upsurge in geriatric population across the world, and increase in awareness about blood & plasma donation. However, factors such as high cost of plasma derivative-based therapy and post-operative risks associated with plasma replacement therapy hamper the market growth. Conversely, the development of enhanced methods for preservation of plasma derivatives along with advanced procedures for fractionation and high potential in untapped markets in the emerging economies are expected to provide lucrative growth opportunities for the market.

The global Blood Plasma Derivatives market was valued at 24800 million US$ in 2018 and will reach 52000 million US$ by the end of 2025, growing at a CAGR of 9.7% during 2019-2025.
This report focuses on Blood Plasma Derivatives volume and value at global level, regional level and company level. From a global perspective, this report represents overall Blood Plasma Derivatives market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Blood Plasma Derivatives in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Blood Plasma Derivatives manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Grifols
SK Plasma
Fusion Health Care
Biotest AG
Green Cross Corporation
Baxter International
LFB
Octapharma AG
CSL Limited
Shire Plc.
China Biologic Products
Kedrion Biopharma
BDI Pharma
Bayer AG
Hualan Biological Engineering

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Albumin
Factor VIII
Factor IX
Immunoglobulin
Hyperimmune Globulin
Others

Segment by Application
Hospitals
Clinics
Other End Users